Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study

Yamamoto-Furusho, Jesus KJesus KYamamoto-FurushoAl Harbi, OthmanOthmanAl HarbiArmuzzi, AlessandroAlessandroArmuzziChan, WebberWebberChanPonce de Leon, EnriqueEnriquePonce de LeonQian, JiamingJiamingQianShapina, MarinaMarinaShapinaToruner, MuratMuratTorunerCHIA-HUNG TUYe, Byong DukByong DukYeGuennec, MorganeMorganeGuennecSison, CeciliaCeciliaSisonDemuth, DirkDirkDemuthFadeeva, OlgaOlgaFadeevaKhan, Qasim M RanaQasim M RanaKhan2024-03-212024-03-212020-0815908658https://www.scopus.com/record/display.uri?eid=2-s2.0-85086570983&doi=10.1016%2fj.dld.2020.05.031&origin=inward&txGid=a6eaa7a3b2c5c2b9eeb476194feba345https://scholars.lib.ntu.edu.tw/handle/123456789/641148Incidence of inflammatory bowel disease (IBD) is increasing in newly industrialised countries (NICs); however, data on suboptimal response to anti-tumor necrosis factor (anti-TNF) agents are limited.enAnti-tumor necrosis factor; Crohn's disease; Suboptimal response; Ulcerative colitis[SDGs]SDG3[SDGs]SDG17Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE studyjournal article10.1016/j.dld.2020.05.031325637212-s2.0-85086570983https://api.elsevier.com/content/abstract/scopus_id/85086570983